Introduction:
Enterprise Therapeutics Ltd. has raised £26m for the Phase IIa trial of ETD001, a novel cystic fibrosis treatment, with investment led by Panakes Partners and participation from existing investors.
- With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m for the Phase IIa study of ETD001, a new therapy for cystic fibrosis.
- ETD001 is a unique compound designed to target the ENaC ion channel, which plays a key role in airway hydration and mucus clearance.
- The therapy aims to significantly improve lung function in cystic fibrosis patients, particularly those who are not eligible for or are not receiving CFTR modulators.
- The funding round also supports Enterprise’s expansion into Italy, where it plans to add clinical investigator sites and advance other preclinical programs targeting mucus congestion.
- Enterprise is focused on developing innovative treatments for respiratory diseases and aims to improve lung function and reduce morbidity in conditions like cystic fibrosis and chronic obstructive pulmonary disease.
Conclusion:
The £26m funding will support the Phase IIa trial of ETD001, a new therapy for cystic fibrosis developed by Enterprise Therapeutics. The unique compound targets the ENaC ion channel and aims to improve lung function in cystic fibrosis patients, particularly those who are not eligible for or are not receiving CFTR modulators. The funding will also support Enterprise’s expansion into Italy and the development of other preclinical programs targeting mucus congestion. This investment highlights the industry’s interest in developing innovative treatments for respiratory diseases and improving patient outcomes.
